Alnylam Pharma (ALNY) Tops Q4 EPS by 46c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $266.11 +0.61%
Revenue Growth %: +15.3%
Financial Fact:
General and administrative: 17.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.3%
Financial Fact:
General and administrative: 17.99M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.39), $0.46 better than the analyst estimate of ($1.85). Revenue for the quarter came in at $335.04 million versus the consensus estimate of $312.2 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
